Cardiovascular Area

Chemotherapy cardiotoxicity 

Breast cancer is the most prevalent in women globally. Advances in screening, early diagnosis, and therapeutic approaches in recent decades have led to a gradual increase in survival rates and life expectancy. This has highlighted the deleterious effect of long-term chemotherapy. We now know that cardiotoxicity is one of the most common complications associated with chemotherapy treatment and that cardiovascular disease is the leading cause of death among cancer survivors. Our objective is focused on the identification of new biological markers, which, together with the established echocardiographic parameters, allow a subclinical diagnosis of cardiac toxicity and a better stratification of the cancer patient, in addition to the identification of possible prevention and treatment routes in preclinical models. 

Epigenetic modulators in cardiovascular disease. 

MicroRNAs are small non-coding ribonucleic acid sequences (18-25nt) that play an essential role in gene expression at the post-transcriptional level. In recent years, the role of microRNAs in cardiovascular pathophysiology has attracted great interest. For this reason, in our group we have focused on studying its role in the pathophysiology of different cardiovascular diseases (heart failure, atrial fibrillation, amyloidosis, Brugada syndrome, etc.).